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In Brief
Intestinal repair is driven by epithelial
stem cells, but how these stem cells are
instructed to initiate repair was unknown.
Here, Romera-Herna´ndez et al. report
that epithelial proliferation after damage
is independent of the stem cell-protective
signal IL-22 but requires ILC3-dependent
amplification of regenerative YAP1
signaling in stem cells.
Cell Reports
ReportYap1-Driven Intestinal Repair Is Controlled
by Group 3 Innate Lymphoid Cells
Mo´nica Romera-Herna´ndez,1,3 Patricia Aparicio-Domingo,1,4 Natalie Papazian,1 Julien J. Karrich,1,5 Ferry Cornelissen,1
Remco M. Hoogenboezem,1 Janneke N. Samsom,2 and Tom Cupedo1,6,*
1Department of Hematology, Erasmus University Medical Center, 3000CA Rotterdam, the Netherlands
2Department of Pediatrics, Division of Gastroenterology, Erasmus University Medical Center, 3000CA Rotterdam, the Netherlands
3Present address: Terry Fox Laboratory, University of British Columbia, Vancouver, BC, Canada
4Present address: Department of Biochemistry, University of Lausanne, Epalinges, Switzerland
5Present address: Department of Hematopoiesis, Sanquin Research, Amsterdam, the Netherlands
6Lead Contact
*Correspondence: t.cupedo@erasmusmc.nl
https://doi.org/10.1016/j.celrep.2019.11.115SUMMARY
Tissue repair requires temporal control of progenitor
cell proliferation and differentiation to replenish
damaged cells. In response to acute insult, group 3
innate lymphoid cells (ILC3s) regulate intestinal
stem cell maintenance and subsequent tissue repair.
ILC3-derived IL-22 is important for stem cell protec-
tion, but the mechanisms of ILC3-driven tissue
regeneration remain incompletely defined. Here we
report that ILC3-driven epithelial proliferation and tis-
sue regeneration are independent of IL-22. In
contrast, ILC3s amplify the magnitude of Hippo-
Yap1 signaling in intestinal crypt cells, ensuring
adequate initiation of tissue repair and preventing
excessive pathology. Mechanistically, ILC3-driven
tissue repair is Stat3 independent, but it involves
activation of Src family kinases. Our findings reveal
that ILC3-driven intestinal repair entails distinct tran-
scriptional networks to control stem cell mainte-
nance and epithelial regeneration, which implies
that tissue repair and crypt proliferation can be influ-
enced by targeting innate immune cells independent
of the well-established effects of IL-22.
INTRODUCTION
The intestinal epithelium forms a physical barrier that prevents
translocation of commensal microorganisms, and defects in in-
testinal barrier integrity or maintenance have severe clinical
impact (Ko¨nig et al., 2016; Peterson and Artis, 2014). Barrier
loss activates deleterious immune responses and can lead to
transmural ulcers and the need for parenteral nutrition (Sonis,
2004). Such complications are major dose-limiting side effects
of high-dose chemotherapy for head-and-neck cancers or dur-
ingmyeloablative conditioning for hematopoietic stem cell trans-
plantation as part of leukemia treatment (Keefe, 2007; Sonis,
2004). Insufficient intestinal barrier repair is a pathological
feature underlying inflammatory bowel disease (IBD) (Hollander
et al., 1986; Odenwald and Turner, 2013). Continuous bacterialThis is an open access article undtranslocation fuels reactivation of microbiota-specific T cells
and subsequent disease recurrence in up to 40% of IBD patients
in remission (Munkholm et al., 1994). Enhancing intestinal epithe-
lial repair, also coinedmucosal healing, has become a sought-af-
ter result in experimental and clinical IBD research, yet the cells
and signals that enhance epithelial regeneration are still ill
defined (Dulai et al., 2015; Florholmen, 2015; Neurath, 2014;
Shah et al., 2016).
In contrast to the potentially deleterious consequences of
overt antibacterial immune activation following barrier loss,
innate immune cell-derived signals positively regulate intestinal
regeneration (Aparicio-Domingo et al., 2015; Lindemans et al.,
2015). Through production of interleukin (IL)-22, group 3 innate
lymphoid cells (ILC3s) safeguard epithelial stem cells after acute
small intestinal damage (Aparicio-Domingo et al., 2015). IL-22 is
constitutively produced by small intestinal ILC3s (Savage et al.,
2017), is important for homeostatic production of antimicrobial
peptides (Liang et al., 2006), and drives stem cell proliferation
in organoid cultures ex vivo (Lindemans et al., 2015).
Intestinal repair is driven by epithelial stem cell differentiation
and subsequent proliferation of progenitor cells in crypts of Lie-
berk€uhn (Barker, 2014). Crypt regeneration is regulated by
signaling pathways activated by signals from local niche cells
(Kabiri et al., 2014; Medema and Vermeulen, 2011; Sato et al.,
2011). Wnt and Notch signals control stem cell self-renewal
(Clevers et al., 2014); in addition, Wnt favors Paneth cell (PC) dif-
ferentiation (van Es et al., 2005), and Notch controls absorptive
versus secretory lineage choices (Tian et al., 2015). Hedgehog
signaling drives progenitor proliferation (van Dop et al., 2010),
while bone morphogenetic proteins (BMPs) activate the peri-
cryptal mesenchyme to support the epithelial stem cell niche
(He et al., 2004). The Hippo-YAP1 pathway is mostly active in
response to damage, inhibiting Wnt and Notch signaling to drive
early differentiation (Gregorieff et al., 2015; Imajo et al., 2015).
IL-22 was also postulated to be a stem cell niche factor, derived
not from structural cells but from intestinal ILC3s, and involved in
intestinal repair (Hanash et al., 2012; Pickert et al., 2009).
In this study, we set out to define the role of ILC3-derived IL-22
during epithelial repair and to mechanistically interrogate this
process.We show that in response to acute small intestinal dam-
age, the stem cell protective cytokine IL-22 is dispensable for
crypt cell proliferation and that in contrast, ILC3s modulateCell Reports 30, 37–45, January 7, 2020 ª 2019 The Author(s). 37
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Differential Regulation of Crypt
Proliferation and Stem Cell Maintenance
(A) Representative H&E staining and crypt histo-
pathology scores of small intestinal sections from
RORgt/, IL-22/, and littermate control mice
four days after MTX.
(B) Representative Ki67 immunostaining and
number of Ki67+ cells in small intestinal crypts of
RORgt/, IL-22/, and littermate control mice
four days after MTX.
(C) Representative flow cytometry plots and fre-
quency of Lgr5-GFP+ cells in duodenal crypts four
days after MTX from Lgr5-GFP+/ mice treated
with neutralizing anti-IL-22 antibodies. Numbers
indicate the percentage of Lgr5-GFP+ cells within
Live(+)CD45()Ter119()CD31()EpCAM1(+)
cells.
(D) Representative Ki67 immunostaining and
number of Ki67+ cells in duodenal crypts four
days after MTX in Lgr5-GFP+/ mice treated
with neutralizing anti-IL-22 antibodies or isotype
controls.
Unpaired Mann-Whitney test, *p < 0.01,
**p < 0.001; statistically not significant (not indi-
cated). Error bars: SEM. Scale bars: 50 mm; n = 4–8
mice per group. See also Figure S1.intestinal repair by controlling the amplitude of Hippo-YAP1
signaling. These findings unveil a unique layer of epithelial regu-
lation, in which evolutionary conserved regenerative pathways
are amplified by cells of the innate immune system, independent
of the well-established effects of IL-22 (Hanash et al., 2012;
Lindemans et al., 2015).
RESULTS AND DISCUSSION
Crypt Cell Proliferation after Stem Cell Damage Is IL-22
Independent
The ILC3-derived cytokine IL-22 positively affects recovery
of Lgr5+ intestinal stem cells from small intestinal crypts
after acute damage and induces epithelial proliferation in vitro38 Cell Reports 30, 37–45, January 7, 2020(Aparicio-Domingo et al., 2015; Linde-
mans et al., 2015). Epithelial repair is
independent of adaptive immunity,
because proliferation of epithelial cells
in response to damage is normal in
Rag2/ mice (Aparicio-Domingo et al.,
2015). To determine the importance of
IL-22 for small intestinal regeneration,
we compared pathology and crypt cell
proliferation after methotrexate (MTX)-
induced damage in IL-22-deficient mice
and ILC3-deficient RORgt/ mice. As
we have shown before, absence of
ILC3s increased tissue pathology in
response to MTX (Aparicio-Domingo
et al., 2015). In contrast, pathology in
IL-22-deficient mice was similar to pa-
thology of IL-22-sufficient littermate con-trols (Figure 1A). As a measure of crypt regeneration, we
enumerated proliferating crypt cells during the regenerative
phase of the response (day 4). This revealed that the severely
reduced proliferation, characteristic of ILC3 deficiency (Apari-
cio-Domingo et al., 2015), was absent from IL-22/ animals,
in which crypt proliferation was indistinguishable from littermate
controls (Figure 1B). We validated the IL-22 deficiency in our
colony by generating Th17 cells from spleens and lymph
node of naive mice and by isolating total T cells from lamina
propria followed by restimulation with IL-23 and transcript anal-
ysis of IL-22 (Figure S1A). This led us to hypothesize that small
intestinal crypt proliferation after acute MTX-induced damage
can occur in an IL-22-independent manner, uncoupled from
IL-22-dependent epithelial stem cell maintenance.
Figure 2. YAP1 Activation Drives Acute Small Intestinal Regeneration
(A) Fragments per kilobase of exon per million fragments mapped (FPKM) values of Yap1 target genes in LGR5-GFPhi crypt cells analyzed by RNA sequencing at
steady state (SS), one and four days after MTX.
(legend continued on next page)
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To test this hypothesis directly, we neutralized IL-22 by anti-
body treatment in Lgr5-GFP stem cell-reporter mice during
exposure to MTX. This allowed combined analyses of stem cell
maintenance and crypt proliferation. Inhibition of IL-22 signaling
was confirmed by downregulation of transcripts encoding proto-
typic IL-22 target genes Reg3g and Reg3b (Figure S1B). Upon
neutralization of IL-22 signaling with antibodies during tissue
damage, maintenance of Lgr5-GFP-expressing cells was
impaired (Figure 1C). In contrast, crypt proliferation was unaf-
fected (Figure 1D) and was similar to that found in control ani-
mals. Altogether, these data reveal that ILC3-dependent stem
cell maintenance and crypt proliferation are mechanistically
distinct responses to insult and that the early proliferative
response following small intestinal injury is IL-22 independent.
YAP1 Signaling Drives Small Intestinal Regeneration
Given that small intestinal crypt proliferation occurred in an
IL-22-independent manner, we set out to identify the epithelial
repair programs activated by acute small intestinal damage. To
this end, we analyzed changes in the epithelial stem cell tran-
scriptome evoked by MTX immediately following induction of
damage (day 1) and during regeneration (day 4). RNA
sequencing of purified Lgr5-GFPhi crypt cells revealed rapid
transcriptional upregulation of target genes of the regenera-
tion-associated Hippo-YAP1 pathway at one and four days
after damage (Figure 2A and PCR validation in Figure S2A).
Activation of YAP1 involves protein de-phosphorylation and
subsequent nuclear translocation. Under homeostatic condi-
tions, YAP1 localization in villus epithelium was exclusively
cytoplasmic, while in crypt epithelial cells, both cytoplasmic
and faint nuclear localization were observed, suggestive of
continuous low-grade YAP1 activation (Figure 2B). MTX expo-
sure induced YAP1 nuclear translocation in crypt epithelial cells
(Figure 2B), in line with the increased transcription of YAP1
target genes. Concomitant to YAP1 activation, transcription of
genes indicative of WNT (Figures 2C and S2B) and Notch (Fig-
ures 2D and S2C) signaling were reduced, in agreement with
YAP1-dependent temporal repression of stem cell self-renewal,
favoring rapid differentiation at the expense of stemness (Barry
et al., 2013; Gregorieff et al., 2015; Yui et al., 2018). Indeed,
transcription of genes associated with stem cell identity were
reduced (Figure 2E), while transcription of genes associated
with mature secretory cells, including goblet cells (GCs), PCs,
and enteroendocrine cells (EECs) were all increased
(Figures 2F and S2D–S2F), as was the proportion of phenotypic
EECs in isolated crypts (Figures 2G and S2G).
YAP1 activates target gene transcription by binding to nu-
clear TEAD transcription factors (Zhao et al., 2008). The inter-(B) Representative YAP1 staining of duodenal sections at the indicated time poin
(C–F) FPKMvalues derived fromRNA sequencing of LGR5-GFPhi crypt cells of gen
signature, and (F) secretory cell identity, including GCs, PCs, and EECs.
(G) Percentages of EECs in small intestinal crypt-derived cell suspensions analyz
CD45()Ter119()CD31()EpCAM1(+)Lgr5-GFP()CD24hiSSClo cells.
(H) Representative H&E staining and crypt pathology scores of small intestine fo
(I) Representative Ki67 immunostaining and quantification of duodenal sections f
FPKM values are plotted for transcripts with statistically significant log2 fold chang
or statistically not significant (not indicated). Unpaired Mann-Whitney test, **p < 0
100 mm (I); n = 3 mice per group (A and C–G), n = 4–8 mice per group (B, H, and
40 Cell Reports 30, 37–45, January 7, 2020action between YAP1 and TEADs can be inhibited by vertepor-
fin, a U.S. Food and Drug Administration-approved drug used
for treatment of macular degeneration (Battaglia Parodi et al.,
2016). To resolve the importance of YAP1 activation for
small intestinal regeneration after MTX-induced damage, we
blocked YAP1-TEAD interactions during MTX exposure.
YAP1 inhibition increased tissue pathology, characterized by
severe crypt abnormalities (Figure 2H) and a significant loss
of crypt cell proliferation (Figure 2I), similar to the loss of
regeneration in ILC3-deficient RORgt/ mice. Altogether,
these findings identify YAP1 activation as a dominant driver
of early small intestinal crypt regeneration following acute
damage.
YAP1 Activation Is Blunted in the Absence of ILC3s
Based on the importance of YAP1 activation and ILC3 pres-
ence for small intestinal regeneration, we hypothesized that
activation of the Hippo-YAP1 pathway is controlled by ILC3
presence. To test this hypothesis, we analyzed YAP1 activation
in mice lacking ILC3s. In RORgt-deficient mice, damage-
induced YAP1 nuclear translocation was strongly reduced
(Figure 3A), leading to a decrease in the percentage of crypts
containing at least one cell per transverse section with nuclear
YAP1 (Figure 3B) and thus an increase in crypts failing to acti-
vate YAP1. To molecularly define crypt responses in the
absence of ILC3s, we crossed Lgr5-GFP reporter mice to
ILC3-deficient RORgt/ mice and analyzed the epithelial
stem cell transcriptome after small intestinal damage by RNA
sequencing. YAP1 activation in LGR5-GFPhi epithelial cells
from mice lacking ILC3s was severely blunted, and relative to
homeostasis, no significant changes could be detected in
most YAP1 target genes (Figures 3C and S3A). Diminished
YAP1 activation was concomitant with failure to reduce WNT
(Figure 3D) and Notch (Figure 3E) target genes and signaling
components and an absence of both loss of stemness (Fig-
ure 3F) and induction of transcripts involved in mature
secretory cell differentiation (Figure 3G). Similarly, the transient
increase in EEC differentiation seen in control crypts (Figure 2G)
was absent from crypts from RORgt/ mice (Figure 3H), high-
lighting the functional consequences of reduced YAP1 activa-
tion. In line with our previous findings on crypt proliferation,
transcription of YAP target genes was independent of adaptive
immunity and occurred normal in RAG1/ mice exposed to
MTX. In contrast, pretreatment of RAG1/ mice with Thy1-
depleting antibodies to broadly delete innate lymphoid cells
(ILCs) hampered induction of YAP targets (Figure S3B). Alto-
gether, these data reveal that the magnitude of Hippo-YAP1
signaling is amplified by presence of small intestinal ILC3s.ts after MTX exposure.
es involved in (C)Wnt signaling, (D) Notch signaling, (E) intestinal stem cell (ISC)
ed by flow cytometry at the indicated time points. EECs were gated as Live(+)
ur days after MTX exposure in the presence of verteporfin or DMSO control.
our days after MTX treatment in the presence of verteporfin or DMSO control.
e (DESeq2 analysis of count data) with **adjusted p < 0.01, *adjusted p < 0.05,
.01, *p < 0.05 (G, H, and I). Error bars: SEM. Scale bars: 10 mm (B), 50 mm (H),
I). See also Figure S2.
Figure 3. YAP1 Activation Is Blunted in the Absence of ILC3s
(A) Representative YAP1 immunostaining of duodenal crypts from RORgt/ mice and littermate controls one day after MTX. Scale bar: 50 mm.
(B) Percentage of duodenal crypts containing at least 1 cell with nuclear translocation of YAP1 in RORgt/ mice and littermate controls one day after MTX.
(C–G) Log2 fold change values determined by RNA sequencing of Lgr5-GFP
hi crypt cells comparing MTX day 1 versus SS for control mice (black bars),
RORgt/ mice (red bars) and MTX day 4 versus SS for control mice (gray bars), or RORgt/ mice (blue bars) showing (C) YAP1 target genes, (D) Wnt-related
genes, (E) Notch-related genes, (F) intestinal stem cell genes, and (G) secretory cell genes.
(H) Percentages of EECs determined by flow cytometry in duodenal crypts at the indicated time points from RORgt/ mice (red bars). Control mice (as in
Figure 2G) are shown for comparison (black bars). EECs were gated as Live(+)CD45()Ter119()CD31()EpCAM1(+)Lgr5-GFP()CD24hiSSClo cells.
Log2 fold change (DESeq2 analysis of count data) with **adjusted p < 0.01, *adjusted p < 0.05, or statistically not significant (not indicated) (C–F). FPKM values are
plotted for transcripts that have statistically significant log2 fold change (DESeq2 analysis of count data) with **adjusted p < 0.01, *adjusted p < 0.05, or statistically
not significant (not indicated). UnpairedMann-Whitney test, *p < 0.01; statistically not significant (not indicated) (B andH). Error bars: SEM. n = 4–8mice per group
(A, B, and H), n = 3 mice per group (C–G). See also Figure S3.Activation of YAP1 Signaling in Intestinal Crypts Is
Independent of IL-22
Our findings indicate that crypt proliferation and Lgr5 cell main-
tenance are independently regulated, fueled by YAP1 and IL-22,
respectively. To assess whether IL-22 has a role in epithelial
YAP1 activation after small intestinal damage, we quantifiedYAP1 activation in epithelial stem cells from mice exposed to
MTX in the presence of IL-22-neutralizing antibodies. Lgr5-GFPhi
crypt cells were analyzed byRNA sequencing one day afterMTX.
The efficacy of IL-22 neutralization was controlled by analysis of
Reg3g and Reg3b transcription in purified PCs (Figure S3C).
IL-22 neutralization did not alter transcripts associated withCell Reports 30, 37–45, January 7, 2020 41
Figure 4. YAP1 Activation Involves gp130-
SFK Signaling
(A) FPKM values of gp130 and gp130 co-receptors
transcribed by Lgr5-GFPhi crypt cells at steady
state and one day after MTX.
(B) FPKM values and relative expression by qPCR
of gp130 ligands transcribed by intestinal
CCR6+NKp46 ILC3s at steady state.
(C) Representative YAP1 immunostaining and
percentage of duodenal crypts containing at least
1 cell with nuclear translocation of YAP1 one day
after MTX treatment in the presence of LMT-28 or
vehicle control.
(D) Representative flow cytometry plots and fre-
quency of Lgr5-GFP+ cells in duodenal crypts four
days after MTX from Lgr5-GFP+/mice treatedwith
STATTIC or DMSO vehicle control. Numbers indi-
cate the percentage of Lgr5-GFP+ cells within
Live(+)CD45()Ter119()CD31()EpCAM1(+) cells.
(E) Representative Ki67 immunostaining and
number of Ki67+ cells in duodenal crypts four days
after MTX in Lgr5-GFP+/ mice treated with
STATTIC or DMSO vehicle control.
(F) Representative YAP1 immunostaining in
duodenal crypts from mice treated with SFK in-
hibitor PP2 or DMSO control one day after MTX.
(G) Representative H&E and Ki67 staining of
duodenal sections four days after MTX treatment
in the presence of PP2 or DMSO control.
(H) Crypt pathology score of small intestinal sec-
tions four days after MTX in mice treated with PP2
or DMSO control.
FPKM values are plotted for transcripts that have
statistically significant log2 fold change (DESeq2
analysis of count data). Unpaired Mann-Whitney
test, *p<0.01 (B); unpaired t test, *p<0.05 (CandD).
Errorbars:SEM.Scalebars: 100mm(DandF), 50mm
(B); n = 3 mice per group (A, C, and D), n = 4–6 mice
per group (B and E–G). See also Figure S4.YAP1 (Figures S3D and S3E), WNT (Figure S3F), or Notch (Fig-
ure S3G) targets or signaling components or transcripts involved
in stemness (Figure S3H) or secretory cell differentiation (Figures
S3I). These data illustrate that IL-22 signaling is dispensable
for YAP1 activation following acute damage to the small
intestine.
YAP1 Activation Requires gp130 Dimerization and Src
Family Kinase Activation
Damage-induced epithelial YAP1 activation can occur in
response to various stimuli, including signaling through the IL-642 Cell Reports 30, 37–45, January 7, 2020family receptor gp130 and mechanoten-
sion in response to altered extracellular
matrix composition (Taniguchi et al.,
2015). Mechanotension-induced YAP1
activation occurs during the later stages
of tissue repair and involves activation of
a discrete set of genes (Yui et al., 2018).
Analyses of these mechanotension-asso-
ciated genes in Lgr5-GFPhi stem cells af-
ter MTX-induced damage showed thatthese genes are either not transcribed or transcribed at similar
levels in ILC3-deficient and control mice (Figures S4A and
S4B), making it unlikely that this pathway is important during
the initial ILC3-dependent activation of epithelial YAP1.
To definewhether ILC3-driven YAP1 involved gp130 signaling,
we first analyzed the transcriptome of Lgr5-GFPhi small intestinal
crypt cells for the presence of gp130 and the cytokine-specific
receptor chains that multimerize with gp130 to form functional
receptor units. Under homeostatic conditions, as well as after
damage, Lgr5-GFPhi crypt cells transcribed gp130, the il11ra1
chain, and low levels of Cntfr (Figures 4A and S4C). IL-6 can
also signal via a soluble IL-6R that complexes with gp130,
thereby precluding the necessity for cell-autonomous IL-6R tran-
scription (Novick et al., 1989). Second, we determined transcrip-
tion of reciprocal ligands for gp130 receptors by intestinal ILC3s.
To this end, we purified CCR6+ ILC3s from the small intestine
and performed transcriptional analyses by RNA sequencing
and qPCR (Figure 4B). This revealed that small intestinal ILC3s
transcribe Lif, Osm, and likely Il6, although there was discrep-
ancy in Il6 detection by RNA sequencing and PCR (Figure 4B).
The IL-6 and IL-11 pathways have been associated with multiple
aspects of tissue regeneration, and alterations in these pathways
are linked to IBD susceptibility and intestinal cancer progression
(Garbers and Scheller, 2013; Katsanos and Papadakis, 2017;
Taniguchi and Karin, 2014). Even though ILC3s do not transcribe
IL-11, stromal cells can produce IL-11, indicating the possible
involvement of a stromal cell relaying ILC3 signals to epithelial
cells, a mechanism that we cannot exclude based on our current
data. The IL-6 and IL-11 receptors use homo-dimerization of
gp130 to form a specific receptor with a single IL-6R or IL-11R
chain. To analyze possible involvement of gp130 homo-dimer-
ization in Yap1 activation, we used a small molecule inhibitor
of this process (LMT-28) (Hong et al., 2015). LMT-28 application
during the induction of small intestinal damage with MTX
reduced nuclear translocation of YAP1 in crypt epithelial cells,
reduced the percentage of crypts containing at least one cell
with nuclear YAP1 per transverse section, and thus increased
the number of crypts that failed to activate YAP1-driven regener-
ation (Figure 4C). Downstream of gp130-associated receptors
signals are transduced either by STAT3 signaling or by activation
of Src family kinases (SFKs) (Taniguchi et al., 2015). To assess
the importance of these two pathways, we inhibited STAT2/3
signaling with the small molecule inhibitor STATTIC and SFK ac-
tivity with the pharmacological inhibitor PP2. Efficiency of STAT
inhibition was controlled by analyses of known STAT3 target
genes (Figure S4D). Inhibition of STAT3 signaling also blocks
IL-22 receptor signaling, highlighted by the failure of Lgr5+
stem cell maintenance following MTX damage (Figure 4D). In
contrast, the YAP1-dependent proliferative response at day 4
after MTX was not affected by STAT2/3 inhibition (Figure 4E),
indicating that STAT molecules are not involved in this process.
Administration of the SFK inhibitor PP2 prevented nuclear
translocation of YAP1 in small intestinal crypt cells (Figure 4F)
and resulted in increased crypt pathology and loss of crypt pro-
liferation (Figure 4G), reminiscent of the regenerative defects in
ILC3-deficient RORgt/ mice. These findings again highlight
the dichotomy between stem cell maintenance, which is both
ILC3 and IL-22 dependent, and crypt proliferation, which is
ILC3 dependent yet IL-22 independent.
Collectively, our findings reveal that the evolutionary
conserved, regeneration-associated Hippo-YAP1 signaling
pathway is amplified by presence of ILC3s, independent of the
stem cell-protective effect of IL-22. This implies that immune
cell-driven tissue regeneration is the sum of multiple parallel
pathways, including the well-established IL-22R signaling
pathway, as well as ILC3-dependent YAP1 activation, as shown
in this report. Themechanistic uncoupling of stem cell protection
and crypt regeneration could suggest that ILC3s act not only on
LGR5-expressing intestinal progenitors but also on additionaldamage-associated epithelial precursor subsets (Ayyaz et al.,
2019; Tian et al., 2011).
Our study does not discriminate between direct and indirect
epithelial activation by ILC3s. ILC3smay be activating a cell pop-
ulation that functions as an intermediate between ILC3s and
epithelial cells, such as crypt-associated mesenchymal stromal
cells. Altering the stromal cells adjacent to the intestinal crypts
could be part of the mechanistic underpinnings of ILC3-driven
tissue repair. Further work is needed to elucidate the exact
ILC3- and YAP1-dependent epithelial repair mechanisms.
YAP1-driven intestinal regeneration is critical for epithelial pro-
liferation after intestinal damage in insects (Karpowicz et al.,
2010; Ren et al., 2010; Shaw et al., 2010). Nevertheless, ILC3s
are present only in mammals and fish (Herna´ndez et al., 2018)
and are lacking from more primitive organisms (Lane et al.,
2009). Combined with our findings, this implies that evolution
favored a complementary layer of crypt regulation driven by
specialized innate immune cells. This paves the way for future
design of novel targeting strategies aimed at activating ILC3-
driven tissue repair in IBD or reducing side effects of anticancer
therapies, independent of IL-22.
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LEAD CONTACT AND MATERIALS AVAILABILITY
This study did not generate new unique reagents. Further information and requests for resources and reagents should be directed to
and will be fulfilled by the Lead Contact, Tom Cupedo (t.cupedo@erasmusmc.nl).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
C57BL/6, B6.129P2(Cg)-Rorctm2Litt/J (RORgt-GFP), IL-22/ (Kindly provided by Genentech, South San Francisco, CA), Lgr5-GFP-
IRES-creERT2 (Lgr5-GFP) and Lgr5-GFP/RORgt-GFPmice were bred at the animal facility of the Erasmus University Medical Center
Rotterdam. Animal experiments were approved by the institutional review board of the Erasmus University Medical Center in the
context of animal experiment license# AVD101002016692. A mix of male and female age-matched mice were used for all
experiments.
METHOD DETAILS
Small intestinal damage
8-12 weeks old mice were injected i.p. with 120mg/kg clinical gradeMethotrexate PCH at day-1 and with 60mg/kg at day 0. Tissues
were collected at day 1 and day 4 after the last MTX injection.
Cytokine modulation during MTX treatment
150 mg anti-IL-22 antibody (8E11, kindly provided by Genentech, South San Francisco, CA) or mouse IgG1 isotype control
(MOPC-21, BioXCell) were administered i.p to Lgr5-GFP+/ mice every 2 days, starting 4 days before the first MTX dose, until day
2 after the last MTX dose. Stattic (Sigma) was injected at day 1 and day 0 at 0.5 mg/ml in 2.5% DMSO. Control mice were injected
with 2.5%DMSO. Verteporfin (Selleckchem) and PP2 (Sigma) were administered at day1, day 0 and day 1 andmice were analyzed
at day 4. Verteporfin was dissolved at a final concentration of 10 mg/injection and PP2 at 1 mg/injection. Both were dissolved in 10%
DMSO. Control mice received 10% DMSO. LMT-28 was injected i.p at 5 mg/kg, at days 1, 0 and 2. Control mice were given the
same volume of saline containing 10% ethanol.
Crypt isolation
Isolation of intestinal crypts was performed as previously described (Sato et al., 2009). Briefly, isolated small intestines were opened
longitudinally and washed with cold PBS. 5 mm pieces were washed with cold PBS, incubated in EDTA (2 mM) at 4C for 30 min and
resuspended in PBS. Crypt-enriched sediments were passed through a 70 mmcell strainer and centrifuged at 200 g for 2min to sepa-
rate the crypts from single cells. Crypts were incubated with 1 mL of TrypLE Express (GIBCO) + Dnase I (Merk Millipore) at 37C for
10-15 min until crypt dissociation was observed. Single cell suspensions were filtered through 40 mm cell strainer and labeled with
conjugated antibodies.
Antibodies
The following antibodies were used for flow cytometry: CD45 (30F11; Invitrogen); EpCAM-1 (G8.8), CD24 (M1/69), CD31 (390),
Ter119 (TER-119;); all from BioLegend. Dead cells were excluded with 7AAD (Beckman coulter). Antibodies used for paraffin immu-
nostaining were: rat anti-mouse Ki67 monoclonal antibody (MIB-5, Dako) and rabbit anti-mouse Yap1 antibody (D8H1X, Cell
signaling).
Flow cytometry and cell sorting
Fc receptors were blocked with appropriate sera or rat-anti-mouse CD16/CD32 (2.4G2; BD Biosciences). All labelings were
performed in PBS containing 2% heat-inactivated fetal calf serum (FCS) at 4C. Labeled cells were analyzed on a FACS LSRII
(BD Biosciences) and data processed with FlowJo software (FlowJo, LLC).
RNA sequencing
cDNA was prepared using SMARTer Ultra Low RNA kit (Clontech Laboratories) for Illumina Sequencing following the manufacturer’s
protocol. For intestinal stem cells and ILC3, sorted cells from 3 individual mice were pooled per data point. The Agilent 2100 Bio-
analyzer and the High Sensitivity DNA kit were applied to determine the quantity and quality of the cDNA production. Amplified
cDNA was further processed according to TruSeq Sample Preparation v.2 Guide (Illumina) and paired end-sequenced (2x75bp)
on the HiSeq 2500 (Illumina). Demultiplexing was performed using CASAVA software (Illumina) and the adaptor sequences were
trimmed with Cutadapt (https://cutadapt.readthedocs.io/en/stable/). Alignments against the mouse genome (mm10) and analysis
of differential expressed genes were performed with DESeq2 in the R environment on the raw fragment counts extracted from the
BAM files by HTSeq-count(Gro¨schel et al., 2014). Cufflinks software was used to calculate the number of fragments per kilobase
of exon per million fragments mapped (FPKM) for each gene.Cell Reports 30, 37–45.e1–e3, January 7, 2020 e2
Histology
Small intestinal tissue pieces (5 mm) or Swiss rolls were fixed in 4% PFA (4h, room temperature), washed in 70% ethanol and
embedded in paraffin. Four-mm sections were deparaffinized and stained with hematoxylin (Vector Laboratories) and eosin
(Sigma-Aldrich). For Ki67 and YAP1 detection, endogenous peroxidases were blocked in 1% periodic acid in deionized water for
20 min, and antigen retrieval was achieved by microwave treatment in citrate buffer (10mM, pH 6.0). Prior to staining, Fc receptors
were blocked in 10% normal mouse serum and 10% of normal serum matching the host species of the secondary antibody, 10 mM
Tris buffer, 5 mMEDTA, 0.15MNaCl, 0.25% gelatin, and 0.05% Tween-20 (pH 8.0). Tissue sections were incubated overnight at 4C
with primary antibodies in PBS supplemented with 2% normal mouse serum. Immunoreactions were detected using biotinylated
donkey anti-rat (Dako) and goat-anti-rabbit (Vector Laboratories) and incubated with the Vectastain ABC Elite Kit (Vector Labora-
tories) and 3,30-diaminobenzidine tetrahydrochloride (Sigma-Aldrich). Sections were counterstained with hematoxylin. Pathology
scores and enumeration of Ki67 and Yap1 were performed blinded. Pathology was scored as previously described (de Koning et
al., 2006) and Ki67-expressing cells were counted in 7 to 15 crypts per section.
Immunohistochemistry
Tissues were frozen in Tissue-Tek O.C.T compound (Sakura Finetek Europe B.V.) and stored at 80C. Six mm cryosections were
fixed for 5 min in ice-cold acetone and air-dried for 10 min, and subsequently blocked with 5% normal mouse serum and 5% normal
donkey serum for 15 min. Sections were incubated with primary antibody for 1 hr. at room temperature, followed by a 30min incu-
bation with secondary antibodies. Sections were embedded in Pro-longGoldwith DAPI (Invitrogen) and analyzed on a Leica DMRXA.
Transcript analysis
RNA was extracted using the NucleoSpin RNA XS kit (Machery Nagel). RNA from sorted cells was amplified with the Ovation PicoSL
WTA System V2 (NuGen) according to manufacturer’s protocol. For quantitative PCR, a Neviti Thermal Cycler (Applied Biosystems)
and SensiFAST SYBR Lo-Rox kit (BioLine) were used, with the addition of MgCl2 to a final concentration of 4 mM. All reactions were
performed in duplicate and normalized to the expression of Gapdh or Cyclophilin. Relative expression was calculated by the cycling
threshold (CT) method as 2-DCT. The primers sequences can be found in Table S1.
QUANTIFICATION AND STATISTICAL ANALYSIS
Samples were analyzed using unpaired Mann-Whitney test or Unpaired t test as indicated in figure legends. P values < 0.05 were
considered significant. Data are shown as mean ± SEM.
DATA AND CODE AVAILABILITY
The accession numbers for the RNA sequencing data reported in this study are ArrayExpress: E-MTAB-6639 and E-MTAB-8387.e3 Cell Reports 30, 37–45.e1–e3, January 7, 2020
